Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ravindhi Murphy"'
Autor:
Caroline Ward, Rohini Sharma, Maria Martinez, Tara Barwick, Eric Aboagye, Gurvin Chander, Ravindhi Murphy, Sairah R Khan, Mitesh Naik
Publikováno v:
BMJ Open, Vol 13, Iss 10 (2023)
Introduction Suitability for peptide receptor radionuclide therapy (PRRT) for neuroendocrine neoplasia (NENs) depends on presence of somatostatin receptor-2 (SSTR2) determined by [68Ga]Ga-DOTA-peptide-positron emission tomography (PET). Some patients
Externí odkaz:
https://doaj.org/article/f62d0091e7594b779b3fccf2cdf8b732
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Modern cancer therapeutics are increasingly targeted, bringing the promise of new and improved activity, alongside better tolerability. However, while many are indeed resulting in dramatic improvements in disease control and patient survival, short-
Externí odkaz:
https://doaj.org/article/0bbf4a7b3d594c28a1a9ebc08cffbed6
Autor:
Geoffrey J. Maher, Rosemary A. Fisher, Baljeet Kaur, Xianne Aguiar, Preetha Aravind, Natashia Cedeno, James Clark, Debbie Damon, Ehsan Ghorani, Adam Januszewski, Foteini Kalofonou, Ravindhi Murphy, Rajat Roy, Naveed Sarwar, Mark R. Openshaw, Michael J. Seckl
Publikováno v:
npj Genomic Medicine, Vol 7, Iss 1, Pp 1-8 (2022)
Abstract Tumours expressing human chorionic gonadotropin (hCG), the majority of which are difficult to biopsy due to their vascularity, have disparate prognoses depending on their origin. As optimal management relies on accurate diagnosis, we aimed t
Externí odkaz:
https://doaj.org/article/4537b0fad97f47fca2fad90941d4c7aa
Autor:
Antonella Cammarota, Valentina Zanuso, Giulia Francesca Manfredi, Ravindhi Murphy, David James Pinato, Lorenza Rimassa
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
The treatment landscape of advanced hepatocellular carcinoma (HCC) has broadened with immune checkpoint inhibitors (ICIs) setting a novel standard of care. With the increased number of therapies either in first or in further line, disentangling the p
Externí odkaz:
https://doaj.org/article/b6a42a98dd9a40569a6c8535eb4b9835
Autor:
Mark P Lythgoe, Jonathan Krell, Mark Bower, Ravindhi Murphy, John Marriott, Sarah P Blagden, Ajay Aggarwal, Richard Sullivan
Publikováno v:
e160
e150
e150
The departure of the UK from the European Union (EU) and affiliated European regulatory bodies on the 31st December 2020, including the European Medicines Agency, (EMA), has resulted in the Medicines and Healthcare products Regulatory Agency (MHRA) b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32639b154c6518cf95cc2129e974e374
http://hdl.handle.net/10044/1/101541
http://hdl.handle.net/10044/1/101541
Autor:
Petros Fessas, Sujit Mukherjee, Nadia Guerra, CN Wong, Ravindhi Murphy, David J. Pinato, Takashi Mineo, Lorenza Rimassa, Francesco Mauri, Rohini Sharma, Mark Thursz
Publikováno v:
Oncogene
Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional char
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98b3c172e753a931ffedc39d32b1f64d
http://europepmc.org/articles/PMC7190571
http://europepmc.org/articles/PMC7190571
Autor:
Sanjay Popat, Maximilian Julve, James Clark, T. Newsom-Davis, Ellis Dell, Adam Januszewski, Ravindhi Murphy
Publikováno v:
Web of Science
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::874da0d29addbc337c28024d5dba170e
https://doi.org/10.1016/s0169-5002(21)00382-2
https://doi.org/10.1016/s0169-5002(21)00382-2
Autor:
Dalia Ahmed, Isra Ferjani, Joanne Evans, Ravindhi Murphy, Saranya Ravindra, Olivia Hatcher, Danielle Power, T. Newsom-Davis, James Clark, Waleed Mohammed
Publikováno v:
Lung Cancer. 156:S46
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91b10b05c644c4d6fefa5ebec53e7422
https://doi.org/10.1016/s0169-5002(21)00309-3
https://doi.org/10.1016/s0169-5002(21)00309-3
Autor:
Ravindhi Murphy, Michael Flynn, Apostolos Konstantis, Elena Takeuchi, Benjamin Sanderson, Fharat Raja, Rebecca Roylance, Farah Rehman, Amy Elizabeth Guppy, Daire Hanna, Emma Spurrell, Karim Keshwani, anna lerner, Elizabeth Sharkey, Charlotte Westbury, Alicia Frances Clare Okines, Ruth E. Board, Judy King
Publikováno v:
Journal of Clinical Oncology. 37:e12525-e12525
e12525 Background: Fulvestrant is a selective oestrogen receptor (ER) down regulator used to treat hormone receptor-positive advanced breast cancer in postmenopausal women. It is used at various time points in treatment. However, variations in fundin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::859a2a238edbe3ee396ca0ce3b087d8d
https://doi.org/10.1200/jco.2019.37.15_suppl.e12525
https://doi.org/10.1200/jco.2019.37.15_suppl.e12525